# Neuraic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuraic

- Industry: Healthcare
- Headquarters: Hangzhou, China
- Latest round: Angel (Jun 23, 2026)
- Investors on record: 5

## About

Based in Hangzhou, China, and founded in 2025, Hangzhou Shenji Miaokong Technology Co., Ltd., trading under the name Neuraic, is a provider of research and development and clinical application services for Brain-Computer Interface (BCI) 3.0 technology. The firm was established by Dr. Gu Huidong, who has over 20 years of experience in medical device research and development. In June 2026, Neuraic raised an Angel+ funding from Hongcheng Investment Management.

The company provides research and development services for third generation invasive brain computer interfaces. Its core offerings include intelligent neural coding software, multi dimensional data collection systems, and targeted clinical therapy protocols for neurological restoration.

The company generates revenue by developing and commercializing implantable brain–computer interface systems and related closed-loop neurotechnology solutions, as well as providing clinical application services, system integration, and optimization of neural signal acquisition and decoding technologies.

The Angel and Angel+ funding will be used to focuses on four main areas:
First, establishing production lines for flexible electrodes and closed-loop brain-computer interface (BCI) devices, and upgrading core hardware; 
Second, continuously optimizing neural decoding AI algorithms and expanding the algorithm R&D and clinical validation team; 
Third, advancing multi-center clinical trials to expand clinical indications for more neurological diseases; 
Fourth, improving the Class III medical device registration and application system to accelerate product clinical trials and seize a first-mover advantage in the domestic and international invasive brain-computer interface (BCI) medical device market.

In the future, Neuraic will continue to adhere to the "three principles" (sustainability, reliability, and safety) to deeply cultivate brain-computer interface 3.0 technology and refine low-invasive, highly stable brain-computer interface diagnostic and treatment devices.

## Funding rounds

- Angel, Jun 23, 2026 — Hongcheng Investment Management
- Angel, May 22, 2026 — Hangzhou High-Tech Investment, Ennovation Ventures, Hangzhou Xihu District Science and Technology Equity Investment, Shanghai Angel Group

## Investors

- Hangzhou High-Tech Investment (https://capitalatlas.ai/funds/hangzhou-high-tech-investment) — Angel
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Angel
- Hangzhou Xihu District Science and Technology Equity Investment — Angel
- Shanghai Angel Group — Angel
- Hongcheng Investment Management (https://capitalatlas.ai/funds/hongcheng-investment-management) — Angel